SB-366791
SIGMA/S0441 - ≥98% (HPLC), powder
Synonym: N-
CAS Number: 472981-92-3
Empirical Formula (Hill Notation): C16H14NO2Cl
Molecular Weight: 287.74
MDL Number: MFCD01033818
Linear Formula: C16H14NO2Cl
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C16H14ClNO2/c1-20-15-4 |
| InChI key | RYAMDQKWNKKFHD-JXMROGBWSA |
| originator | GlaxoSmithKline |
| Quality Level | 200 ![]() |
| SMILES string | COc1cccc(NC(=O)C=Cc2ccc |
| solubility | DMSO: 5 mg/mL, clear |
| Application: | SB-366791 has been used as a transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist: • to infer the in vitro and in vivo pharmacology of (E)-3-(4-t-butylphenyl)-N • to study its effects on sodium hydrogen sulfide (NaHS) or capsaicin-induced contractile activity • to study the inhibitory potency of phoneutria toxin (PnTx3-5) (native and recombinant) on various responses mediated by transient receptor potential cation channel subfamily V member 1 (TRPV1) |
| Biochem/physiol Actions: | SB-366791 might exhibit analgesic properties on bone cancer-related pain behavior. |
| Biochem/physiol Actions: | Vanilloid receptor-1 (TRPV1) antagonist. |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |

